(Q33411956)

26 July 2017

Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement (English)

1 reference

26 July 2017

Rodney D Gilbert

4

0 references

author name string

Hushi Hu

series ordinal

1

1 reference

26 July 2017

Arvind Nagra

series ordinal

2

1 reference

26 July 2017

Mushfequr R Haq

series ordinal

3

1 reference

26 July 2017

8 December 2013

1 reference

26 July 2017

1 reference

26 July 2017

29

1 reference

26 July 2017

6

1 reference

26 July 2017

1103-1106

1 reference

https://scigraph.springernature.com/pub.10.1007/s00467-013-2709-z

26 July 2017

0 references

cites work

Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2709-Z

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2709-Z

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2709-Z

Complement therapy in atypical haemolytic uraemic syndrome (aHUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2709-Z

Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2709-Z

Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2709-Z

Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2709-Z

Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2709-Z

Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2709-Z

Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2709-Z

Cisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of CD46 treated with eculizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2709-Z

Eculizumab in severe Shiga-toxin-associated HUS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2709-Z

Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2709-Z

Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24317637

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00467-013-2709-Z

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference